Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...

Cell and Gene Therapy
Optimize your process and prepare for scale up with fewer trials
Accuracy
DOE design to reliably predict optimal conditions for process development
Time saving
Reduce time spend on process development
Expertise
Take advantage of our +20 years expertise in optimization of upstream processes
While the potential benefits of CGT to patients seem clear, the high costs are hard for healthcare systems to carry. A single dose of a treatment can cost millions of dollars which makes access to those therapies very restricted. To be able to reach the full potential of cell and gene therapies in curing diseases, stakeholders need to focus on the ability to manufacture bioproducts concentrated in high quality and efficacious titers. However, viral manufacturing is not simple, with multiple complex challenges ranging from starting material generation, ensuring cellular production of high titers of viral vectors, to purification, where not all viral particles contain the intended genetic payload.
To define optimal conditions for a specific process, we support our customers with a free viral vector DoE (Design of Experiment) service, as part of our scientific support Compared to the, one-factor-at-a-time (OFAT) method, DoE is the most cost-efficient way to design experiments, increase productivity, save time, and tackle the toughest challenges in process development.
These FAQs are organized by application to guide you to find the best answer possible.
You have access to all the documents related to the transfection reagent.
Search for publications in our Transfection Database with Polyplus transfection reagents
This lexicon will help you to understand the different terms related to Polyplus-transfection®.